The skinny on weight loss drugs

The new class of weight loss drugs melts away excess pounds, but could its effects spill beyond the health-care industry?

As the obesity epidemic rages across the globe, new weight loss drugs have become so popular that some manufacturers are unable to meet patient demand. Dr David Katz, founder and CEO of Diet ID, joins Double Take to discuss investment ramifications of these hotly demanded medications.

PRESENTED BY

Raphael J. Lewis

Head of specialist research

Jack Encarnacao

Research analyst, investigative, Specialist Research team

TOPICS

GLP-1s: Beyond Weight Loss

What happens when a weight loss drug starts changing behavior and consumption?

23 June 2026 Raphael J. Lewis Jack Encarnacao

Betting on the future with prediction markets

How are investors using prediction markets to inform investment decisions?

13 May 2026 Raphael J. Lewis Jack Encarnacao

Greenland: The new frontier

Greenland is moving from the edge of the map to the centre of global conversations.

15 April 2026 Raphael J. Lewis Jack Encarnacao

RELATED CONTENT

GLP-1s: Beyond Weight Loss

What happens when a weight loss drug starts changing behavior and consumption?

23 June 2026 Raphael J. Lewis Jack Encarnacao

Betting on the future with prediction markets

How are investors using prediction markets to inform investment decisions?

13 May 2026 Raphael J. Lewis Jack Encarnacao

Greenland: The new frontier

Greenland is moving from the edge of the map to the centre of global conversations.

15 April 2026 Raphael J. Lewis Jack Encarnacao

See all insights

EXPLORE TOPICS